This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
BioMarin Pharmaceutical Inc.
Drug Names(s): Vibriolysin Topical
Description: Vibrilase is being developed for burn debridement and has recently completed Phase I clinical trials.Vibrilase is a protease secreted by Vibrio proteolyticus, a marine microorganism. Vibrilase has the property of digesting necrotic tissue—fibrin, elastin, collagen etc. The protease activity of Vibrilase is specific for denatured proteins, leaving healthy tissue unharmed. In addition, studies in a porcine model demonstrated that Vibrilase treatment is not accompanied by bleeding, is compatible with burn treatment therapies, such as skin grafting, is stable in a hydrophilic medium at ambient temperatures and has a long shelf life.
Partners: Merck KGaA
Pink Sheet Trademark Review
Additional information available to subscribers only: